文献速递心力衰竭与心肌病心律失常

胺碘酮与植入式心律转复除颤器在恰加斯心肌病中的随机临床试验

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

CHAGASICS 试验将 323 例 Rassi 评分≥10 分且有非持续性室速的慢性恰加斯心肌病患者随机分至 ICD 或胺碘酮组,中位随访 3.6 年。

要点

  • ICD 未降低全因死亡率,与胺碘酮组无显著差异。
  • ICD 显著降低心脏性猝死风险(HR 0.25,95%CI 0.10-0.61)。
  • ICD 降低需起搏的心动过缓和心衰住院风险。

核心结论

  • 在慢性恰加斯心肌病中高危患者中,ICD 未降低全因死亡风险,但显著降低心脏性猝死、起搏需求和心衰住院风险。

研究设计与样本

  • CHAGASICS 为开放标签随机临床试验,自巴西 13 个中心纳入 323 例患者,随机 1:1 接受 ICD 或胺碘酮治疗。
  • 纳入标准为恰加斯病血清学阳性、Rassi 风险评分至少 10 分且至少 1 次非持续性室速发作。
  • 研究因行政原因提前终止,原计划纳入 1100 例,实际随机 323 例(胺碘酮组 166 例,ICD 组 157 例),中位随访 3.6 年(IQR 1.8-4.4)。

主要发现

  • 患者平均年龄 57.4(9.8)岁,男性 185 例(57.3%),平均左室射血分数 37.0%(11.6%)。

关键数值与推荐

  • Rassi 风险评分至少 10 分(中高危)且至少 1 次非持续性室速发作者符合入选条件。
  • 胺碘酮组在随机化后给予 600 mg 负荷剂量。
  • 主要终点为全因死亡率,次要终点包括心脏性猝死、心衰住院和全程随访中需起搏器的情况。

临床怎么用

  • 对于慢性恰加斯心肌病中高危患者,ICD 虽未改善总生存,但可显著减少心脏性猝死和心衰住院,并降低起搏需求。
  • 临床决策需权衡 ICD 对特定终点(猝死、起搏、心衰住院)的获益与全因死亡率无改善的结果。

局限性

  • 研究因行政原因提前终止,样本量仅 323 例,低于原计划的 1100 例。
  • 开放标签设计可能引入偏倚。
  • 结果需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Over 10 000 people with Chagas disease experience sudden cardiac death (SCD) annually, mostly caused by ventricular fibrillation. Amiodarone hydrochloride and the implantable cardioverter-defibrillator (ICD) have been empirically used to prevent SCD in patients with chronic Chagas cardiomyopathy. OBJECTIVE: To test the hypothesis that ICD is more effective than amiodarone therapy for primary prevention of all-cause mortality in patients with chronic Chagas cardiomyopathy and moderate to high mortality risk, assessed by the Rassi score. DESIGN, SETTING, AND PARTICIPANTS: CHAGASICS is an open-label, randomized clinical trial. The study enrolled patients from 13 centers in Brazil from May 30, 2014, to August 13, 2021, with the last follow-up November 8, 2021. Patients with serological findings positive for Chagas disease, a Rassi risk score of at least 10 points (intermediate to high risk), and at least 1 episode of nonsustained ventricular tachycardia were eligible to participate. Data were analyzed from May 3, 2022, to June 16, 2023. INTERVENTIONS: Patients were randomized 1:1 to receive ICD or amiodarone (with a loading dose of 600 mg after randomization). MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, and secondary outcomes included SCD, hospitalization for heart failure, and necessity of a pacemaker during the entire follow-up. RESULTS: The study was stopped prematurely for administrative reasons, with 323 patients randomized (166 in the amiodarone group and 157 in the ICD group), rather than the intended 1100 patients. Analysis was by intention to treat at a median follow-up of 3.6 (IQR, 1.8-4.4) years. Mean (SD) age was 57.4 (9.8) years, 185 patients (57.3%) were male, and the mean (SD) left ventricular ejection fraction was 37.0% (11.6%). There were 60 deaths (38.2%) in the ICD arm and 64 (38.6%) in the amiodarone group (hazard ratio [HR], 0.86 [95% CI, 0.60-1.22]; P = .40). The rates of SCD (6 [3.8%] vs 23 [13.9%]; HR, 0.25 [95% CI, 0.10-0.61]; P = .001), bradycardia requiring pacing (3 [1.9%] vs 27 [16.3%]; HR, 0.10 [95% CI, 0.03-0.34]; P < .001), and heart failure hospitalization (14 [8.9%] vs 28 [16.9%]; HR, 0.46 [95% CI, 0.24-0.87]; P = .01) were lower in the ICD group compared with the amiodarone arm. CONCLUSIONS AND RELEVANCE: In patients with chronic Chagas cardiomyopathy at moderate to high risk of mortality, ICD did not reduce the risk of all-cause mortality. However, ICD significantly reduced the risk of SCD, pacing need, and heart failure hospitalization compared with amiodarone therapy. Further studies are warranted to confirm the evidence generated by this trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01722942.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Martinelli-Filho M, Marin-Neto JA, Scanavacca MI, et al. Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 39356542. doi:10.1001/jamacardio.2024.3169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。